All Blogs

Jul 29, 2015

DelveInsight, the leading market research and consulting company has added new report  Bile Duct Cancer (Cholangiocarcinoma) -Pipeline Insights, 2015 to its portfolio. With this launch DelveInsight now has 700+ Reports on Indication Pipeline Insight. In addition to this, our research expertise provides our clients w...

Jul 24, 2015

In current scenario chemotherapies and radiations are prominently used to cure cancer which results in adverse effects. Oral Mucositis is one such adverse effect that results in ulceration in the mouth due to high dosage of chemotherapy. The patients undergoing head and neck cancer chemotherapy are at a high risk of...

Jul 23, 2015

Cancer is one of the pioneer causes of obliteration. Although a lot of therapies are being developed in this area but still there is a high unmet need. Currently companies are getting inclined towards Immunotherapies which are target specific (monoclonal and conjugated antibodies) and effective. One such therapy are...

Jul 16, 2015

DelveInsight, the leading market research and consulting company has added Oncology based Reports to its portfolio. With this launch DelveInsight now has 100+ Oncology based Reports. In addition to this, our research expertise provides our clients with up to date information of market till the date on which order is...

Jul 07, 2015

DelveInsight expertise over 400+ Indication Active Pharmaceutical Ingredient (API) Reports DelveInsight, leading Market Research and Business Consulting firm has an expertise in providing business solutions to Pharma and biotech companies. DelveInsight has 400+ Indication API reports on wide range of therapeutic ...

Jun 30, 2015

“We designed CAR T cells to overcome a number of problems in getting T cells to attack Cancer”-says Eshhar, after the development of first CAR-T cells (1989). CAR-T Technologies and History of Innovations Ever so often in the history of immunotherapy, there comes a breakthrough that takes cancer research ...

Jun 17, 2015

In the field of oncology, no other approach is as attentive as Immunotherapy. Renewed interest in immunotherapy has been driven by Chimeric Antigen Receptor (CAR) T-cell therapy. This emerging approach is (CAR) T-cell technology which is showing great promise in immunotherapy. There are 35+ products in pipeline and...

Jun 13, 2015

DelveInsight is Hiring!!! Looking for Passionate Candidates Mail your updated Resume to careers@delveinsight.com JOB DESCRIPTION Profile Offered: Analyst (2-4 years Experienced) Education: M. Pharma/M.tech Biotech/MBA Biotech/B.Tech/ Roles and Responsibilities: Excellent editing, verbal and written ...

Jun 03, 2015

Drugs with better pharmacodymics and improved treatment algorithm with antiproliferative and anti-inflammatory treatments are needed! Pulmonary arterial hypertension (PAH) is rare lung disorder affecting pulmonary arteries. It is a fatal disease associated with the vasoconstriction and vascular remodeling that i...

May 04, 2015

The current cancer therapies and drug design strategies developed are more precisely aimed at targeting the cancer cells. Primary challenge in selectively targeting cancer cells is to differentiate between the cancer cells and the normal cells. One such difference is enzyme telomerase activity which has been an exc...